PMID- 24303866
OWN - NLM
STAT- MEDLINE
DCOM- 20141003
LR  - 20140128
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 43
IP  - 2
DP  - 2014
TI  - Diminished complement-activating capacity through the classical pathway in sera 
      from type 2 diabetes mellitus.
PG  - 170-81
LID - 10.3109/08820139.2013.864161 [doi]
AB  - Complement-activating capacity through the classical pathway in type 2 diabetes 
      mellitus (T2DM) was examined in the context of free sialic acid as a potential 
      modulator of complement activation. Complement-activating capacity was 
      investigated in an incubation study of heat-aggregated IgG (HAG) and sera from 42 
      T2DM patients. The study demonstrated diminished in-vitro complement-activating 
      capacity through the classical pathway in T2DM. Various doses of N-acetyl 
      neuraminic acid (NANA) were incubated with normal serum and HAG. Complement 
      activation product levels decreased in a NANA dose-dependent manner. 
      Isoelectrofocusing analysis in a mixture of NANA and purified C3 indicated that 
      C3 changed pI dose-dependently, resulting in the downregulation of complement 
      activation. The serum levels of free sialic acid were determined by fluorometric 
      assay in the 42 T2DM sera samples, and were significantly increased in patients 
      with diminished complement activation. These data indicate that increased serum 
      sialic acid may become a candidate for decreasing complement-activating capacity 
      in T2DM.
FAU - Fujita, Takayuki
AU  - Fujita T
AD  - Department of Nephrology, Hypertension and Endocrinology, Nihon University School 
      of Medicine , Tokyo , Japan.
FAU - Hemmi, Seiichiro
AU  - Hemmi S
FAU - Kajiwara, Mamiko
AU  - Kajiwara M
FAU - Yabuki, Minako
AU  - Yabuki M
FAU - Fuke, Yoshinobu
AU  - Fuke Y
FAU - Satomura, Atsushi
AU  - Satomura A
FAU - Soma, Masayoshi
AU  - Soma M
LA  - eng
PT  - Journal Article
DEP - 20131204
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Complement C3)
RN  - 0 (Immunoglobulin G)
RN  - GZP2782OP0 (N-Acetylneuraminic Acid)
SB  - IM
MH  - Aged
MH  - Complement C3/metabolism
MH  - *Complement Pathway, Classical
MH  - Diabetes Mellitus, Type 2/*immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*metabolism
MH  - Immunomodulation
MH  - Male
MH  - Middle Aged
MH  - N-Acetylneuraminic Acid/immunology/*metabolism
MH  - Serum/*metabolism
EDAT- 2013/12/07 06:00
MHDA- 2014/10/04 06:00
CRDT- 2013/12/06 06:00
PHST- 2013/12/06 06:00 [entrez]
PHST- 2013/12/07 06:00 [pubmed]
PHST- 2014/10/04 06:00 [medline]
AID - 10.3109/08820139.2013.864161 [doi]
PST - ppublish
SO  - Immunol Invest. 2014;43(2):170-81. doi: 10.3109/08820139.2013.864161. Epub 2013 
      Dec 4.